DPP-4 INHIBITOR THERAPY IN PATIENTS AFTER PANCREATIC TRANSPLANT

Area of Science:

• Transplantation immunology
• Endocrinology
• Pharmacology

Background:

• Hyperglycemia management after pancreas transplantation (PT) is not well-established.
• Limited data exists on effective and safe interventions for post-PT hyperglycemia.
• Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely available and used for hyperglycemia.

Purpose of the Study:

• To investigate the hypothesis that early intervention with a DPP-4 inhibitor prolongs insulin-free graft function in PT patients.
• To evaluate the efficacy of sitagliptin in managing post-transplant hyperglycemia.

Main Methods:

• Retrospective chart review of 26 patients with noninsulin-dependent hyperglycemia at least 1 year post-PT.
• Comparison between a standard therapy group (observation until insulin required) and an intervention group (early sitagliptin).
• Median follow-up of 45 months, comparing time to insulin requirement.

Main Results:

• No difference in time to hyperglycemia onset after PT between groups.
• Significantly longer time to insulin requirement in the intervention group (early sitagliptin) versus standard therapy (P<.001).
• This difference remained significant after adjusting for BMI (P<.001).

Conclusions:

• Early treatment of post-PT hyperglycemia with DPP-4 inhibitors, like sitagliptin, extends the time to insulin therapy.
• This suggests a potential benefit over standard observation for managing hyperglycemia after pancreas transplantation.
• Further prospective studies are recommended to confirm these findings.